{"entity":{"type":"insider","cik":"0001920738","url":"/insider/0001920738","json_url":"/insider/0001920738.json","name":"Bizily Scott","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":40,"n_filings":28,"first":"2022-12-05","last":"2026-08-17","span_basis":"filed_date"},"name_variants":[{"name":"Bizily Scott","source":"filing","n_filings":28,"first_seen":"2022-12-05","last_seen":"2026-08-17"}],"transactions":[{"id":9255777,"accession":"0001193125-26-354313","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-354313","line_url":"/filing/0001193125-26-354313#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1635.0,"shares_display":"1,635","price_per_share":12.2,"price_display":"12.20","price_state":"stated","total_value":19947.0,"total_display":"19,947.00","total_whole":"19,947","shares_owned_after":8617.0,"shares_owned_after_display":"8,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-17","filed_date":"2026-08-17","scope":"insider"},{"id":9255776,"accession":"0001193125-26-354313","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-354313","line_url":"/filing/0001193125-26-354313#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1635.0,"shares_display":"1,635","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":19620.0,"total_display":"19,620.00","total_whole":"19,620","shares_owned_after":8617.0,"shares_owned_after_display":"8,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-13","filed_date":"2026-08-17","scope":"insider"},{"id":5877346,"accession":"0001920738-26-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001920738-26-000004","line_url":"/filing/0001920738-26-000004#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6566.0,"shares_display":"6,566","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":91924.0,"total_display":"91,924.00","total_whole":"91,924","shares_owned_after":8617.0,"shares_owned_after_display":"8,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-30","filed_date":"2026-07-02","scope":"insider"},{"id":5902488,"accession":"0001920738-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001920738-26-000002","line_url":"/filing/0001920738-26-000002#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9810.0,"shares_display":"9,810","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":117720.0,"total_display":"117,720.00","total_whole":"117,720","shares_owned_after":8617.0,"shares_owned_after_display":"8,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-23","filed_date":"2026-06-25","scope":"insider"},{"id":4031750,"accession":"0001193125-25-326851","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-326851","line_url":"/filing/0001193125-25-326851#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1635.0,"shares_display":"1,635","price_per_share":10.9,"price_display":"10.90","price_state":"stated","total_value":17821.5,"total_display":"17,821.50","total_whole":"17,822","shares_owned_after":3594.0,"shares_owned_after_display":"3,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-16","filed_date":"2025-12-19","scope":"insider"},{"id":4880123,"accession":"0001193125-25-288632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-288632","line_url":"/filing/0001193125-25-288632#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1635.0,"shares_display":"1,635","price_per_share":10.59,"price_display":"10.59","price_state":"stated","total_value":17314.65,"total_display":"17,314.65","total_whole":"17,315","shares_owned_after":3594.0,"shares_owned_after_display":"3,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-17","filed_date":"2025-11-19","scope":"insider"},{"id":4298269,"accession":"0001193125-25-251874","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-251874","line_url":"/filing/0001193125-25-251874#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2678.0,"shares_display":"2,678","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":32136.0,"total_display":"32,136.00","total_whole":"32,136","shares_owned_after":3594.0,"shares_owned_after_display":"3,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-24","filed_date":"2025-10-27","scope":"insider"},{"id":4066322,"accession":"0001193125-25-243946","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-243946","line_url":"/filing/0001193125-25-243946#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1635.0,"shares_display":"1,635","price_per_share":10.17,"price_display":"10.17","price_state":"stated","total_value":16627.95,"total_display":"16,627.95","total_whole":"16,628","shares_owned_after":5188.0,"shares_owned_after_display":"5,188","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-16","filed_date":"2025-10-20","scope":"insider"},{"id":5143205,"accession":"0001193125-25-238995","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-238995","line_url":"/filing/0001193125-25-238995#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2408.0,"shares_display":"2,408","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":24080.0,"total_display":"24,080.00","total_whole":"24,080","shares_owned_after":5188.0,"shares_owned_after_display":"5,188","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-09","filed_date":"2025-10-14","scope":"insider"},{"id":5025239,"accession":"0001193125-25-221028","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-221028","line_url":"/filing/0001193125-25-221028#line-1","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2407.0,"shares_display":"2,407","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":19256.0,"total_display":"19,256.00","total_whole":"19,256","shares_owned_after":7596.0,"shares_owned_after_display":"7,596","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-23","filed_date":"2025-09-26","scope":"insider"},{"id":2142753,"accession":"0000950170-24-107903","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-107903","line_url":"/filing/0000950170-24-107903#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":16.33,"price_display":"16.33","price_state":"stated","total_value":8165.0,"total_display":"8,165.00","total_whole":"8,165","shares_owned_after":6781.0,"shares_owned_after_display":"6,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-18","scope":"insider"},{"id":2037582,"accession":"0000950170-24-099505","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-099505","line_url":"/filing/0000950170-24-099505#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500.0,"total_display":"7,500.00","total_whole":"7,500","shares_owned_after":6781.0,"shares_owned_after_display":"6,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-19","filed_date":"2024-08-21","scope":"insider"},{"id":2305330,"accession":"0000950170-24-084725","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-084725","line_url":"/filing/0000950170-24-084725#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":27.11,"price_display":"27.11","price_state":"stated","total_value":47442.5,"total_display":"47,442.50","total_whole":"47,443","shares_owned_after":6781.0,"shares_owned_after_display":"6,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-16","filed_date":"2024-07-18","scope":"insider"},{"id":2417751,"accession":"0000950170-24-083712","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-083712","line_url":"/filing/0000950170-24-083712#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1996.0,"shares_display":"1,996","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":49900.0,"total_display":"49,900.00","total_whole":"49,900","shares_owned_after":6781.0,"shares_owned_after_display":"6,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-11","filed_date":"2024-07-15","scope":"insider"},{"id":2461273,"accession":"0000950170-24-081626","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-081626","line_url":"/filing/0000950170-24-081626#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4248.0,"shares_display":"4,248","price_per_share":21.3648,"price_display":"21.36","price_state":"stated","total_value":90757.6704,"total_display":"90,757.67","total_whole":"90,758","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-01","filed_date":"2024-07-03","scope":"insider"},{"id":2417480,"accession":"0000950170-24-075692","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-075692","line_url":"/filing/0000950170-24-075692#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":23.7106,"price_display":"23.71","price_state":"stated","total_value":41493.55,"total_display":"41,493.55","total_whole":"41,494","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-20","scope":"insider"},{"id":2636912,"accession":"0000950170-24-062637","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-062637","line_url":"/filing/0000950170-24-062637","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":25.4520252,"price_display":"25.45","price_state":"stated","total_value":44541.0441,"total_display":"44,541.04","total_whole":"44,541","shares_owned_after":2204.0,"shares_owned_after_display":"2,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-16","filed_date":"2024-05-20","scope":"insider","n_lines":2},{"id":2850260,"accession":"0000950170-24-045702","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-045702","line_url":"/filing/0000950170-24-045702#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":25.74,"price_display":"25.74","price_state":"stated","total_value":45045.0,"total_display":"45,045.00","total_whole":"45,045","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-16","filed_date":"2024-04-18","scope":"insider"},{"id":2204574,"accession":"0000950170-24-041418","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-041418","line_url":"/filing/0000950170-24-041418#line-5","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8153.0,"shares_display":"8,153","price_per_share":31.78,"price_display":"31.78","price_state":"stated","total_value":259102.34,"total_display":"259,102.34","total_whole":"259,102","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-01","filed_date":"2024-04-03","scope":"insider"},{"id":3109396,"accession":"0000950170-24-038731","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-038731","line_url":"/filing/0000950170-24-038731#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5833.0,"shares_display":"5,833","price_per_share":35.0438,"price_display":"35.04","price_state":"stated","total_value":204410.4854,"total_display":"204,410.49","total_whole":"204,410","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-27","filed_date":"2024-03-29","scope":"insider"},{"id":2141262,"accession":"0000950170-24-034227","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-034227","line_url":"/filing/0000950170-24-034227#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":31.27,"price_display":"31.27","price_state":"stated","total_value":54722.5,"total_display":"54,722.50","total_whole":"54,723","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-18","filed_date":"2024-03-20","scope":"insider"},{"id":3151350,"accession":"0000950170-24-023330","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-023330","line_url":"/filing/0000950170-24-023330#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1909.0,"shares_display":"1,909","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":57270.0,"total_display":"57,270.00","total_whole":"57,270","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-29","scope":"insider"},{"id":2767588,"accession":"0000950170-24-018155","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-018155","line_url":"/filing/0000950170-24-018155#line-3","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750.0,"shares_display":"1,750","price_per_share":27.67,"price_display":"27.67","price_state":"stated","total_value":48422.5,"total_display":"48,422.50","total_whole":"48,423","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-16","filed_date":"2024-02-21","scope":"insider"},{"id":2673944,"accession":"0000950170-24-014119","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-014119","line_url":"/filing/0000950170-24-014119","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6244.0,"shares_display":"6,244","price_per_share":27.5,"price_display":"27.50","price_state":"stated","total_value":171710.0,"total_display":"171,710.00","total_whole":"171,710","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider","n_lines":3},{"id":8451560,"accession":"0001610717-23-000153","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-23-000153","line_url":"/filing/0001610717-23-000153#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FMDT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal and HR Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal and HR Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal and HR Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":20.85,"price_display":"20.85","price_state":"stated","total_value":78187.5,"total_display":"78,187.50","total_whole":"78,188","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-08","filed_date":"2023-06-12","scope":"insider"},{"id":8592941,"accession":"0001610717-23-000098","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-23-000098","line_url":"/filing/0001610717-23-000098#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FMDT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal and HR Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal and HR Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal and HR Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2247.0,"shares_display":"2,247","price_per_share":18.3103,"price_display":"18.31","price_state":"stated","total_value":41143.2441,"total_display":"41,143.24","total_whole":"41,143","shares_owned_after":1737.0,"shares_owned_after_display":"1,737","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-01","filed_date":"2023-06-06","scope":"insider"},{"id":8625966,"accession":"0001140361-23-020316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-23-020316","line_url":"/filing/0001140361-23-020316#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal and HR Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal and HR Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal and HR Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3750.0,"shares_display":"3,750","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":75000.0,"total_display":"75,000.00","total_whole":"75,000","shares_owned_after":2109.0,"shares_owned_after_display":"2,109","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-21","filed_date":"2023-04-25","scope":"insider"},{"id":8046132,"accession":"0001567619-23-004430","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-23-004430","line_url":"/filing/0001567619-23-004430#line-2","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal and HR Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal and HR Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal and HR Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2248.0,"shares_display":"2,248","price_per_share":19.3,"price_display":"19.30","price_state":"stated","total_value":43386.4,"total_display":"43,386.40","total_whole":"43,386","shares_owned_after":2109.0,"shares_owned_after_display":"2,109","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":6687245,"accession":"0001567619-22-021291","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001567619-22-021291","line_url":"/filing/0001567619-22-021291","is_derivative":false,"issuer_cik":"0001650648","issuer_name":"4D Molecular Therapeutics, Inc.","issuer_ticker":"FDMT","issuer_name_source":null,"issuer_url":"/issuer/0001650648","owner_cik":"0001920738","owner_name":"Bizily Scott","owner_display_name":"Bizily Scott","owner_url":"/insider/0001920738","role":"Officer (Chief Legal and HR Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal and HR Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal and HR Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":22.787500416666667,"price_display":"22.79","price_state":"stated","total_value":136725.0025,"total_display":"136,725.00","total_whole":"136,725","shares_owned_after":3157.0,"shares_owned_after_display":"3,157","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-01","filed_date":"2022-12-05","scope":"insider","n_lines":9}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":40,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":40,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":40},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001650648","name":"4D Molecular Therapeutics, Inc.","url":"/issuer/0001650648","role":"Officer (Chief Legal Officer)","n_filings":28,"first_seen":"2022-12-05","last_seen":"2026-08-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001920738","retrieved_at":"2026-08-26T19:23:35+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}